|Bid||278.50 x 800|
|Ask||281.50 x 800|
|Day's range||278.61 - 286.00|
|52-week range||223.25 - 468.55|
|Beta (5Y monthly)||0.47|
|PE ratio (TTM)||22.49|
|Earnings date||20 Oct 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||397.48|
Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.
Here are three highly profitable stocks that Wall Street thinks will soar 39% or more within the next 12 months. The consensus price target for Bristol Myers Squibb (NYSE: BMY) is 39% above the big drugmaker's current share price. This forward earnings multiple is well below the average forward price-to-earnings ratio of 13.4 for pharmaceutical stocks in the S&P 500.
CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced topline results from its pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense oligonucleotide (ASO) drug being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), will be presented at the upcoming American Neurological Association (ANA) 2021 virtual meeting, October 17-19, 2021. ANA Presentation Details:Sunday, October 17, 2021, 4:20 p